US Q2 2026 Earnings Wave: ResMed +16% EPS, Ardelyx +31% Revenue, WillScot Guidance Raised

The Quick Take

• ResMed (RMD) reports 9% revenue growth and 16% EPS expansion in Q4 FY2026; WillScot Holdings raises full-year guidance on sustained modular workspace activation demand
• Ardelyx (ARDX) posts 31% revenue growth on kidney disease drug XPHOZAH despite payer challenges; ICU Medical delivers 6% organic revenue growth with raised EBITDA guidance
• Fox Factory beats EBITDA guidance and raises full-year sales outlook; Enact Holdings reports strong earnings with raised capital return commitments across Q2 2026

Q2 2026 earnings season continued to deliver broadly positive surprises across US small- and mid-cap names in healthcare technology, industrial services, and specialty pharmaceuticals. The breadth of beats across 68 companies signals resilient demand despite macro caution, with guidance raises outnumbering cuts in most sectors tracked.

ResMed Inc (RMD) led medical device performance with 9% revenue growth and 16% EPS expansion in Q4 FY2026, navigating its Astral product recall challenges while maintaining strong cost discipline. WillScot Holdings Corp (WSC) posted 4% revenue growth and raised its full-year guidance, citing robust modular workspace activation demand that has proved durable through the current economic cycle. Ardelyx Inc (ARDX) surged 31% in revenue on strength from XPHOZAH, its FDA-approved phosphate binder for chronic kidney disease, though management revised guidance lower citing payer-imposed formulary barriers that are constraining volume uptake.

ICU Medical Inc (ICUI) delivered 6% organic revenue growth with raised full-year adjusted EBITDA and EPS guidance, while disclosing a bolt-on acquisition that extends its infusion therapy platform. Fox Factory Holding Corp (FOXF) overcame persistent aluminum cost pressures and supply chain volatility to beat EBITDA guidance and raise its full-year sales outlook as premium bicycle and powersports component demand held firm. The cluster collectively highlights healthcare devices, specialty pharma, and industrial modular infrastructure as the sectors showing the most consistent Q2 2026 execution heading into a pivotal H2.

Synthesized from 68 sources.